In a multicenter study of over 370 women who had surgery for ovarian cystic lesions without acute symptoms, researchers found that 42 percent of the resected lesions were deemed to have an O-RADS ultrasound risk score of 2, which has less than a one percent chance of malignancy.

With the capability of identifying possible cases of aortic value stenosis (AVS) from existing electrocardiograms (ECGs), the AI-powered screening software from AccurKardia may facilitate earlier diagnosis of AVS, which is fatally missed in 50 percent of patient who have this condition.

Is it plausible that the current emphasis on spending what it takes to recruit and retain radiologists in a thriving job market shifts to more and more of a dependence on AI?

While staffing shortages in radiology continue to persist after the COVID-19 pandemic, current and emerging innovations powered by artificial intelligence (AI) may help facilities navigate these challenges and mitigate rising costs of health care.

PSMA PET/CT revealed progressive PCa in 31 percent of patients who demonstrated greater than a 50 percent decline in PSA level after treatment with either an androgen receptor-targeted agent or chemotherapy.

Catch up on the top radiology content of the past week.

The clearance may facilitate improved standardization and efficiency of dosimetry-guided, theranostic applications of radiopharmaceutical therapy.

In a study looking at the impact of experience and case volume of breast screening radiologists, researchers found that reviewing more than 150 cases per week was necessary to achieve an 80 percent rate of true-positive assessments for malignant calcifications.

Mean artificial intelligence (AI) scoring for breasts developing cancer was double that of contralateral breasts at initial biennial screening and was 16 times higher at the third biennial screening, according to a study involving over 116,000 women with no prior history of breast cancer.

For patients with extremely dense breasts, contrast-enhanced mammography offered greater than 60 percent higher sensitivity than low-energy mammography for diagnosing breast cancer, according to new research.

In a recent interview, Bridget Koontz, M.D., discussed the capability of the PET imaging agent 18F-flotufolastat for diagnosing post-prostatectomy recurrence of prostate cancer in patients with PSA values less than 1 ng/mL, based on research presented at the American Society for Radiation Oncology (ASTRO) conference.

Review the case and test your knowledge to make the correct diagnosis.

Through analysis of coronary computed tomography angiography (CCTA) images, the PlaqueIQ software provides quantification and classification of atherosclerosis, a common cause of myocardial infarction (MI) and ischemic stroke.

In a multicenter study of over 1,100 patients with COVID-19, pleural effusion was detected on CT scans in nearly a third of patients, who also had significantly higher ICU admission and 30-day mortality rates.

Noting a rapidly changing paradigm for the treatment of rectal cancers, the authors of a new literature review discuss current and emerging principles in MRI assessment and staging.

The inclusion of the 3D imaging technology PlatinumTomo in the Mammomat B.brilliant device reportedly enables clinicians to obtain 50-degree 3D images in less than five seconds.

Eschewing the pursuit of sweet spots with RVUs, this radiologist emphasizes consistent variety in your case mix to help ensure optimal marketability.

Catch up on the top radiology content of the past week.

Offering higher diagnostic efficacy than SPECT imaging for coronary artery disease (CAD) detection, the PET myocardial perfusion imaging agent Flyrcado™ (flurpiridaz F 18, GE HealthCare) provides unit dose availability and effectiveness in imaging patients with high BMI.

Omitting biopsy procedures in men with PSA levels > 3 ng/ml and negative MRI findings for prostate cancer (PCa) was associated with significantly lower risks of diagnosing clinically insignificant PCa in comparison to the use of systematic biopsy, according to an approximately four-year study of over 13,000 men who had prostate cancer screening.